%PDF-1.4
%
44 0 obj
<>
endobj
41 0 obj
<>
endobj
92 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-05-11T11:23:27Z
2024-03-28T12:49:48-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-28T12:49:48-07:00
application/pdf
Heather
2004-367.june
uuid:a8a5b522-1dd1-11b2-0a00-4d0927bd7700
uuid:a8a5b525-1dd1-11b2-0a00-900000000000
endstream
endobj
30 0 obj
<>
endobj
31 0 obj
<>
endobj
45 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 18 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 20 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 22 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 24 0 R/Type/Page>>
endobj
106 0 obj
[110 0 R]
endobj
107 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
53.468 76.5 m
558.468 76.5 l
S
0 0 0 0 k
494.29 69.365 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_0 1 Tf
8 0 0 8 541.468 56.4344 Tm
(1117)Tj
ET
0 0 0 0 k
/GS0 gs
103.631 81.583 407.5 -10.833 re
f*
0.5 w
/GS1 gs
103.631 81.583 407.5 -10.833 re
S
/GS0 gs
53.532 70.509 203 -16.989 re
f*
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.532 56.2548 Tm
[(Bannwarth, et al: )17.7 (A)36.9 (T)0.1 (P)-257.3 (in low back pain)]TJ
/T1_1 1 Tf
0.1489 Tw 10 0 0 10 54 734.8264 Tm
[(However)39.7 (, the clinical relevance for this is uncertain inas-)]TJ
0.00529 Tw 0 -1.2 TD
(much as the use of dextropropoxyphene and acetaminophen)Tj
-0.0303 Tw T*
(combination tablets was lower than expected in both groups.)Tj
0.166 Tw 1.2 -1.2 Td
[(Finally)64.8 (, oral )54.8 (A)110.8 (T)0.2 (P)-379.3 (appeared to be safe. No severe drug)]TJ
-0.0054 Tw -1.2 -1.2 Td
(related adverse event was recorded in patients receiving this)Tj
0.02499 Tw T*
(compound; only 2 patients complained of dyspepsia.)Tj
0.0204 Tw 1.2 -1.2 Td
[(In summary)64.8 (, our study suggests that oral )54.8 (A)110.8 (T)0.2 (P)-233.7 (might pro-)]TJ
0.0994 Tw -1.2 -1.2 Td
[(vide some benefits in patients with subacute LBP)110.7 (, with an)]TJ
0.24429 Tw T*
[(early acting ef)17.7 (fect and a lower use of rescue analgesia.)]TJ
0.0099 Tw T*
[(However)39.7 (, the current evidence is insuf)17.7 (ficient to recommend)]TJ
0.00909 Tw T*
[(this drug for people with LBP)110.7 (. Further studies are needed to)]TJ
0.08681 Tw T*
[(answer the following questions: \(1\) )17.7 (What are the bioavail-)]TJ
0.0498 Tw T*
[(ability and the pharmacokinetic properties of oral )54.8 (A)110.8 (TP? \(2\))]TJ
0.0403 Tw T*
[(What are its mechanisms of action in LBP? \(3\) )17.7 (What is the)]TJ
0.18919 Tw T*
[(most ef)17.7 (fective dosage? \(4\) Is oral )54.8 (A)110.8 (T)0.2 (P)-402.5 (useful in treating)]TJ
0.06799 Tw T*
[(patients with LBP)-281.2 (whatever the duration of symptoms? \(5\))]TJ
-0.0036 Tw T*
[(Does oral )54.8 (A)110.8 (T)0.2 (P)-209.7 (decrease the intake of all types of analgesics,)]TJ
0.02499 Tw T*
(including non-steroidal antiinflammatory drugs?)Tj
/T1_2 1 Tf
0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/T1_1 1 Tf
0.0257 Tw 8 0 0 8 54 496.8264 Tm
[(W)79.9 (e gratefully acknowledge MGRecherches and the investigators who par-)]TJ
0.02499 Tw 0 -1.25 TD
[(ticipated in this study)64.8 (.)]TJ
/T1_2 1 Tf
0 Tw 10 0 0 10 54 462.8264 Tm
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 61.2 452.8264 Tm
[(1.)-600.1 (Hick GS, Duddleston DN, Russell LD, Holman HE, Shepherd JM,)]TJ
1.35 -1.25 Td
[(Brown CA. Low back pain. )54.8 (Am J Med Sci 2002;324:207-1)36.8 (1.)]TJ
-1.35 -1.25 Td
[(2.)-600.1 (Pengel LHM, Herbert RD, Maher CG, Refshauge KM. )54.8 (Acute low)]TJ
1.35 -1.25 Td
(back pain: systematic review of its prognosis. BMJ 2003;327:323-5.)Tj
-1.35 -1.25 Td
[(3.)-600.1 (Abenhaim L, Rossignol M, )17.7 (V)110.8 (alat JP)110.8 (, et al. )17.7 (The role of activity in the)]TJ
1.35 -1.25 Td
(therapeutic management of back pain. Report of the International)Tj
T*
[(Paris )17.7 (T)69.9 (ask Force on Back Pain. Spine 2000;25 Suppl:1S-33S.)]TJ
-1.35 -1.25 Td
[(4.)-600.1 (Deyo RA, Rainville J, Kent DL. )17.7 (What can the history and physical)]TJ
1.35 -1.25 Td
[(examination tell us about low back pain? JAMA)-220.2 (1992;268:760-5.)]TJ
31.65 45.421 Td
[(5.)-600.1 (De Seze S. Randomized, double-blind, placebo-controlled trial of)]TJ
0 Tw 1.35 -1.25 Td
(At\216pad\217ne)Tj
0 Tc 6 0 0 6 370.2012 728.8341 Tm
(\250)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 376.9598 726.1941 Tm
(in back pain [French]. Gazette M\216dicale 1987;90:62-6.)Tj
-6.47 -1.25 Td
[(6.)-600.1 (Kichenin K, Seman M. Chronic oral administration of )54.8 (A)110.8 (T)0.1 (P)]TJ
1.35 -1.25 Td
(modulates nucleoside transport and purine metabolism in rats. )Tj
T*
[(J Pharmacol Exp )17.7 (Ther 2000;294:126-33.)]TJ
-1.35 -1.25 Td
[(7.)-600.1 (Kichenin K, Decollogne S, )54.8 (Angignard J, Seman M. Cardiovascular)]TJ
1.35 -1.25 Td
[(and pulmonary response to oral administration of )54.8 (A)110.8 (T)0.1 (P)-238.2 (in rabbits. )]TJ
0 Tc T*
[(J )54.9 (Appl Physiol 2000;88:1962-8.)]TJ
-0.00011 Tc -1.35 -1.25 Td
[(8.)-600.1 (V)110.8 (an )17.7 (T)35 (ulder MW)91.7 (, )17.7 (T)69.9 (ouray )17.7 (T)74 (, Furlan )54.8 (AD, Solway S, Bouter LM.)]TJ
1.35 -1.25 Td
(Muscle relaxants for nonspecific low back pain: a systematic review)Tj
T*
(within the framework of the Cochrane collaboration. Spine)Tj
0 Tc 0 Tw T*
(2003;28:1978-92. )Tj
-0.00011 Tc 0.02499 Tw -1.35 -1.25 Td
[(9.)-600.1 (Mathieu P)110.7 (, Richard M, )17.7 (V)59.8 (ignon E. Intramuscular dif)17.7 (fusion and )]TJ
1.35 -1.25 Td
[(ef)17.7 (ficacy of )54.8 (At\216pad\217ne)]TJ
0 Tc 0 Tw 6 0 0 6 406.4313 608.8341 Tm
(\250)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 413.1899 606.1941 Tm
(in back pain [French]. Rhumatologie)Tj
0 Tc 0 Tw -9.6487 -1.25 Td
(1988;40:8.)Tj
-0.00011 Tc 0.02499 Tw -1.85 -1.25 Td
[(10.)-600.1 (Roland M, Morris R. )54.8 (A)-220.1 (study of the natural history of low back)]TJ
1.85 -1.25 Td
(pain: Part 1. Development of a reliable and sensitive measure of )Tj
T*
(disability in low-back pain. Spine 1983;8:141-4.)Tj
-1.8131 -1.25 Td
[(1)36.8 (1)-0.1 (.)-600.1 (Coste J, Le Parc JM, Ber)17.7 (ge E, Delecoeuillerie G, Paolaggi JB.)]TJ
1.8131 -1.25 Td
(Adaptation and validation in French of a disability rating scale for)Tj
T*
[(low back pain patients \(the EIFEL)-238.2 (questionnaire\). Rev Rhum Engl)]TJ
0 Tc T*
(Ed 1993;60:295-301.)Tj
-0.00011 Tc -1.85 -1.25 Td
[(12.)-600.1 (Roland M, Fairbanck J. )17.7 (The Roland-Morris Disability Questionnaire)]TJ
1.85 -1.25 Td
[(and the Oswestry Disability Questionnaire. Spine 2000;25:31)36.8 (15-24.)]TJ
-1.85 -1.25 Td
[(13.)-600.1 (Karjalainen K, Malwivaara )54.8 (A, )17.7 (V)110.8 (an )17.7 (T)35 (ulder M, et al. Multidisciplinary)]TJ
1.85 -1.25 Td
(biopsychological rehabilitation for subacute low back pain among)Tj
T*
(working age adults. Cochrane Database Syst Rev)Tj
0 Tc 0 Tw T*
(2003\(2\):CD002193.)Tj
-0.00011 Tc 0.02499 Tw -1.85 -1.25 Td
[(14.)-600.1 (Bombardier C, Hayden J, Beaton DE. Minimally clinically)]TJ
1.85 -1.25 Td
[(important dif)17.7 (ference. Low back pain: outcome measures. )]TJ
T*
(J Rheumatol 2001;28:431-8.)Tj
-1.85 -1.25 Td
[(15.)-600.1 (Stratford PW)91.7 (, Binkley JM, Riddle DL, Guyatt GH. Sensitivity to)]TJ
1.85 -1.25 Td
(change of the Roland-Morris Back Pain Questionnaire: part I. Phys)Tj
T*
[(Ther 1998;78:1)36.8 (186-96.)]TJ
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
24 0 obj
<>stream
8;Z\7>B7V8#itt$j>rig@0%<;Lc@UJgU-Jrij#^#.eDSR5]7ernE3p!Uir;J/3fs0
QkF&n]_LS_Sqs_Kf"R^Z8QNq"ouMDfT`k@WS`)WaHG,?*mq\*>R\Lc5UCZp"b\KH*
H]hLIWLt0GTI8?g9OR2?S*%\paPpBKYmG@3R^iXV_e3MHW,Sh=II550i3]+;WMAV@
./-^&=:;_4oc1n!C#R^D[?K3NMXqP4U2=8s8IGG'GpS.&_=g0M@m01A,O(VkI-%ES
I)M%GIlB1loU:`FX:@0=#;H,IYu>?Uq7.T&AR*9UC#("KaloI'jN$hFjIP]kiF&;H
`Hi\h+"\^%KS"C4o!0URU8k$Ap3'ir4mq!HdG;LZ/]8?__q$THncZLrS7^Nt>n>q:
%EF)s)"B5]XIsI9';Y"6]:Y!m,Or&hXM''mp>i>VVBMI.gTF:q5-%BKp>MlLB\6]H
(^pV$_-lbBTE];I[)5+lChBA1N;o_4P1s5+pcnNm!'U*]OT~>
endstream
endobj
28 0 obj
[/Indexed/DeviceRGB 255 27 0 R]
endobj
27 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
47 0 obj
<>
endobj
59 0 obj
<>
endobj
10 0 obj
<>
endobj
83 0 obj
<>
endobj
97 0 obj
<>
endobj
12 0 obj
<>
endobj
13 0 obj
<>stream
H\TkPWv辰=35X*ᡬQ㋸$A`0=<̀"F"&)QU*hVtu]cܜlkvuJ4DEQThŋV3lSte7Bҩ14vīA~HBˋshl0#pM|gLPMQ'çM
5ϚS(>560mvJ5g+qv!6ݺ6ðЖm3,Y>`5
˔6ò[/Tj0\!5=#;U2XDŚ[a]`Hk&-o͔nJLWwVQRS3AjUJ5BH"TU75P?
1~C]^ޠGt:'aLsBCNj-6(+B3;شrh>ɻWSsD91}A.1^{3xD4A<|
FN8GsNƑO6fOǥ^0&W{c goKnuAHGL&,$;;E| &ȕ3eG;O)?*I!Q$;`8pI2:Y
.H-I]Q滤 >W+=ӝ+>#JBO/JQ1g] }ν\ξm[Nhao˹+_*)˹a5͛$|4_%>6
ZtHӽW٭F5E9 ¶)0ٮ;x6Gn
x.ûSDy8)7y+5V\0LN^R[!*nIdEa5Nc7aZ\KRwdvH:ΚP 28ivii]/3;햑rQn -EqXB%;xŦQT_ ^-OԂ
܌wab9WL4$ cq2/T|.`d&@4{}
cmcGݩO&R7